key: cord-0289785-9y9lkt4x authors: Jergovič, Mladen; Uhrlaub, Jennifer L.; Watanabe, Makiko; Bradshaw, Christine M.; White, Lisa M.; LaFleur, Bonnie J.; Edwards, Taylor; Sprissler, Ryan; Worobey, Michael; Bhattacharya, Deepta; Nikolich-Žugich, Janko title: Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccination date: 2021-07-22 journal: bioRxiv DOI: 10.1101/2021.07.22.453287 sha: a43a3e26effe0c305a6f48e85e4d3dbfae72c084 doc_id: 289785 cord_uid: 9y9lkt4x Aging is associated with a reduced magnitude of primary immune responses to vaccination and constriction of immune receptor repertoire diversity. Clinical trials demonstrate high efficacy of mRNA based SARS-CoV-2 vaccines in older adults but concerns about virus variant escape have not been well addressed. We have conducted an in-depth analysis of humoral and cellular immunity against an early-pandemic viral isolate and compared that to the P.1. (Gamma) and B.1.617.2 (Delta) variants, as well to a B.1.595 SARS-CoV-2 isolate bearing Spike mutation E484Q, in <55 and >65 age cohorts of mRNA vaccine recipients. As reported, robust immunity required the second dose of vaccine. Older vaccine recipients exhibited an expected 3-5x reduction (but not a complete loss) in neutralizing antibody titers against both P.1. (Gamma) and the B.1.595 virus at the peak of the boosted response. However, older vaccinees manifest robust cellular immunity against early-pandemic SARS-CoV-2 and more recent variants, which remained statistically comparable to the adult group. While the duration of these immune responses remains to be determined over longer periods of time, these results provide reasons for optimism regarding vaccine protection of older adults against SARS-CoV-2 variants and inform thinking about boost vaccination with variant vaccines. eTOC summary Vaccine responses are often diminished with aging, but we found strong responses to SARS-CoV-2 in older adults following mRNA vaccination. T cell responses were not diminished when confronted by SARS-CoV-2 variants. Neutralizing Ab were reduced but not more than those in adults. Graphical Abstract Created with BioRender.com the immune response to the COVID mRNA vaccines was measurable, but smaller than 99 expected for humoral immunity, and equal to that found in adults for cellular immunity, 100 suggesting that these vaccines will provide considerable protection even as variants 101 continue to emerge. A total of 25 participants were enrolled in our study before receiving either the 105 BNT162b2 (Pfizer) or mRNA-1273 (Moderna) COVID vaccine. Blood draws were 106 collected prior to initial dose of vaccine, 7-9, and 18-26 days after first vaccine dose, 107 and 7-14 days and 2-3 months after their second dose. These time points are 108 designated as T0, T1, T2, T3, and T4 on all graphs. One participant was excluded from 109 the study because they had a high neutralizing antibody titer and a strong antigen (Ag) CoV-2, which in Spike bears only E484Q and D614G, demonstrates that E484Q also 133 affords the virus an opportunity to escape neutralization. Antibody assays are considered the gold-standard when assessing the quality of 135 immunity after vaccination because antibodies can provide sterilizing immunity. Figure 3A ). Both groups of participants 143 had a small (0.1-0.3% of all B cells) but detectable population of antigen specific cells double positive for S1 and RBD tetramer ( Figure 3A ). This population increased as a 145 percentage of B cells post vaccination in all but two (one from each cohort) participants 146 with no difference between groups ( Figure 3B ). Similar results were obtained with S1 between cohorts for S1+RBD+ double positive cells ( Figure 3C ) or S1 single positive 152 cells ( Figure 3E ). Next, we examined the phenotype of the SARS-CoV-2 specific B cells 153 (gating strategy in Figure S1 ) with respect to class switching, as it has been previously 154 reported that aging is associated with a decline in the percentage and numbers of responses. 180 We also analyzed Ag-specific T cell responses to stimulation with Spike protein peptide 181 pools from WA1 versus two variants of concern by ELISpot. Participant PBMC's were Study participants 244 This study was approved by the University of Arizona IRB (Protocol#2102460536). We 245 collected blood from 16 adults <55 years old (mean age 31.3 ± 6.2) and 9 above 65 246 years old (71 ± 5.2). Demographics are provided in Table I Expression of CD21 (Classical memory) was also equal between <55 and >65 cohorts. Mann-Whitney U test, for all statistical differences *p<0.05, **p<0.01, ***p<0.001. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Key role of T cell defects in age-related vulnerability to West 433 The Journal of experimental medicine Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot 436 assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans Age-related immune response 439 heterogeneity to SARS-CoV-2 vaccine BNT162b2 Immunosenescence and human vaccine immune 441 responses Aging Down-Regulates the Transcription Factor Activation-Induced Cytidine Deaminase, and Ig Class Switch in Human B Cells Aged mice exhibit a severely diminished CD8 T cell response 446 following respiratory syncytial virus infection Targets of T cell responses to SARS-CoV-2 coronavirus in 449 humans with COVID-19 disease and unexposed individuals', Cell Impact and effectiveness of mRNA BNT162b2 vaccine against 452 SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a 453 nationwide vaccination campaign in Israel: an observational study using national 454 surveillance data Defective Transcriptional Programming of Effector CD8 T 457 Cells in Aged Mice Is Cell-Extrinsic and Can Be Corrected by Administration of IL-12 Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA 460 vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-461 blind phase 1 study The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity 464 and Antigenicity Single-cell landscape of bronchoalveolar immune cells in patients 467 with COVID-19' COVID-19 in older people: A rapid clinical review Correlates of protection against SARS-CoV-2 in rhesus 472 macaques The twilight of immunity: emerging concepts in aging of the 474 immune system Antigen-Specific Adaptive Immunity to SARS-477 CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T 480 cell responses Efficacy, safety, and tolerability of herpes zoster vaccine 482 in persons aged 50-59 years Immune Responses to COVID-19 mRNA Vaccines in Patients 485 with Solid Tumors on Active, Immunosuppressive Cancer Therapy', medRxiv : the 486 preprint server for health sciences Lifelong CMV infection improves immune defense in old 489 mice by broadening the mobilized TCR repertoire against third-party infection Efficacy and Safety of the mRNA-1273 SARS-CoV-2 493 Vaccine A SARS-CoV-2 Variant with L452R and E484Q Neutralization 496 Resistance Mutations Analysis of SARS-CoV-2 variant mutations reveals neutralization 499 escape mechanisms and the ability to use ACE2 receptors from additional species Age-associated decline in T cell repertoire diversity leads to 502 holes in the repertoire and impaired immunity to influenza virus Do antibody responses to the influenza vaccine persist year-505 round in the elderly? A systematic review and meta-analysis